PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the Journal of the American College of Cardiology published a new subgroup analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrating that switching to Angiomax® (bivalirudin) after pre-treatment with heparin (UFH or enoxaparin) results in comparable ischemic outcomes and approximately 50 percent reduction in major bleeding compared to consistent heparin therapy plus routine glycoprotein IIb/IIIa inhibitor (GPI) for acute coronary syndrome (ACS) patients undergoing early invasive treatment.1
